Weight-loss drug Mounjaro launched in India after drug regulator approval
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's drug regulator, it said on Thursday.
Global demand for Lilly's diabetes and weight-loss drugs has soared, with the launch presenting a big market opportunity for the US-based drug company as India, world's most populous country, is seeing increasing rates of obesity and diabetes.
"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India.
India has about 101 million people living with diabetes and obesity, a chronic relapsing disease, is a major risk factor for diabetes, Lilly said.
Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weight-loss. It is sold as Zepbound for obesity in the US.
CEO David Ricks told Reuters in February last year that Lilly expects to launch Mounjaro in India as early as 2025.
Analysts have projected global obesity drug sales reaching $150 billion a year by the early 2030s.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
2 hours ago
- The National
Prozac users in the UAE concerned as supplies of 'life-changing' drug dry up
Prozac users in the UAE are concerned about dwindling supplies after its global discontinuation last year, sparking conversations among patients and psychiatrists about available alternatives. Considered a cornerstone treatment for conditions like depression and anxiety, the medication is now fast disappearing from pharmacy shelves as stocks dry up. Internationally, the medication is widely available under other brand names however in the UAE Prozac has historically been the only option with this formula. Finding alternatives Prozac, which was manufactured by US drug company Lilly, is the brand name for fluoxetine, a type of medication known as a selective serotonin reuptake inhibitor (SSRI). It has been used for mental health conditions, including depression, anxiety, obsessive-compulsive disorder, premenstrual dysphoric disorder and bulimia nervosa since its launch in 1987. It is available on the market as a controlled medication and accessible to patients when prescribed by a psychiatrist. Now, patients may have to source their medication out of the country or try alternative pharmaceuticals, such as Zoloft (sertraline) or Cipralex (escitalopram), which have different base formulations and therefore different side effects depending on a person's biology. 'This decision is not related to the safety or efficacy of the medicine, but reflects the availability of broad alternative treatments and evolving business priorities,' a Lilly spokesperson told The National. 'We encourage patients currently on Prozac to speak to their healthcare provider about treatment options available to them. While no new supplies are being planned, limited stock may still be available locally through licensed distributors.' The National was able to locate some Prozac at pharmacies with leftover stocks at the time of writing, but many contacted were completely out. Global antidepressants usage While Prozac has been one of the most widely prescribed drugs of its kind for decades, the global antidepressant market is growing rapidly. It was valued at $18.7 billion in 2024 and is estimated to increase at a compound annual growth rate of 7.5 per cent from 2025 to 2034, when it is forecasted it will be worth $37.9 billion, according to Global Market Insights. This is being driven predominantly by mental health awareness and rising demand for effective treatments for various conditions. 'Impact was life-changing' One Dubai-based mother, who wished to remain anonymous, is concerned for her 11-year-old daughter, who has been taking Prozac for the past 18 months. "She is autistic and struggles with severe anxiety, OCD and specific phobias," she told The National. "We tried other SSRIs before, but none were effective. Prozac has been the only medication that made a noticeable difference, particularly for her OCD symptoms." The mother said since they'd heard Prozac is going out of stock in the UAE, they've been trying to source an alternative fluoxetine product from their home country. "Switching to another SSRI is not a viable option for her right now ... I trust that the authorities will take this matter seriously and work toward a solution, especially for children and families who rely on this medication for daily functioning and well-being." Dubai resident Victoria McKeown, who lived with 'crippling' anxiety for years until she was prescribed Prozac, is also concerned about the lack of availability in the future. 'While I wouldn't describe myself as clinically depressed, I tried several antidepressants over the years with little effect,' she told The National. 'That changed when I was prescribed a low dose of Prozac. The impact was life-changing – not just for me, but for those around me.' Ms McKeown's psychiatrist contacted her to say she will need to consider trying medications that had previously been ineffective. 'Right now, it seems my only option is to travel overseas, obtain a prescription there, and bring it back with me," she said. "It's incredibly disheartening that a medication which has helped so many people is no longer available here.' Experts are hopeful that an appropriate alternative will soon be available in the market, however. Dr Teizeem Dhanji, a child and adolescent psychiatrist and medical director at Dubai's Sage Clinics, said there is currently no confirmed guidance from authorities, but 'it is expected that substitute options will be introduced in due course'. The National has contacted the Emirates Drug Establishment for more details on when an alternative will be registered, but there was no confirmation at the time of writing. What patients can do now Dr Dhanji advised individuals taking fluoxetine to consult their treating psychiatrists to discuss the best course of action. 'Clinicians can help develop a personalised plan to safely and gradually taper the current medications and transition to an appropriate alternative if necessary," she said. "There are a number of safe and effective antidepressant options available in the UAE and so patients should consult their psychiatrist early.' It may also give some individuals the chance to reassess treatment needs and explore additional coping strategies or therapeutic options that may complement or replace medication, Dr Dhanji added. But the disruption could have a significant impact on the market, said Antony Bainbridge, head of clinical services and clinical lead at Resicare Alliance, a UK-based assessment and residential provider for children with mental health issues that plans to open a Dubai boarding facility soon. Mr Bainbridge said the lack of a substitute could require potentially disruptive changes in medication, particularly for patients who respond well to fluoxetine. 'Alternative SSRIs like sertraline, citalopram and paroxetine are available, but they have different side effect profiles and may not be as effective for every individual.' Patients switching from Prozac to another SSRI may experience withdrawal symptoms, relapse or other side effects during the transition, he added. 'The unavailability may lead to worsening of symptoms in some patients, increasing the burden on mental health services.' Mr Bainbridge also expressed concerns that patients could resort to unregulated or illegal sources to obtain the medication, 'posing significant safety risks'.
Middle East Eye
a day ago
- Middle East Eye
Israeli strike kills two near aid distribution centre in southern Gaza
An Israeli air strike on civilians near the aid distribution point in the west of Rafah, in southern Gaza, killed at least two people, according to health officials at the Nasser Medical Complex. Civil defence spokesman Mahmud Bassal and witnesses said the civilians had been heading to a site run by the US-backed Gaza Humanitarian Foundation. Witness Abdallah Nour al-Din told AFP that "people started gathering in the Al-Alam area of Rafah" in the early morning. "After about an hour and a half, hundreds moved toward the site and the army opened fire," he said. At a charity kitchen in Gaza City, displaced Palestinian Umm Ghassan said she had been unable to collect aid from a GHF site "because there were so many people, and there was a lot of shooting." "I was afraid to go in, but there were people who risked their lives for their children and families," she said.
Tourism Breaking News
a day ago
- Tourism Breaking News
marhaba partners with PRIME Health to provide world-class travel services for Dubai's medical tourists
Post Views: 41 marhaba has partnered with PRIME Health to provide premium travel services for passengers arriving in Dubai for medical treatment. Driven by a commitment to patient well-being, the partnership ensures a smooth and stress-free travel experience that complements the quality of care provided by PRIME Health. marhaba will provide its full airport hospitality offering to support medical travellers, including its signature Meet & Greet, Chauffeur and Lounge services. In addition, its recently announced Check-in Anywhere and Land & Leave solutions will further enhance the journey, enabling a smooth, hands-free experience from arrival to departure. Jaffar Dawood, dnata's Divisional Senior Vice President – UAE Airport Operations, said: 'We are pleased to partner with PRIME Health to further enhance the medical tourism experience in Dubai. With marhaba's personalised service and Arabian hospitality, twinned with Dubai's world-class infrastructure, we ensure medical travellers feel looked after from the moment they land. This partnership reflects our shared focus on care, comfort and service excellence.' Dr. Jamil Ahmed, Founder and Managing Director, PRIME Health, said: 'At PRIME Health, we believe exceptional care starts well before a patient enters the hospital. Our partnership with marhaba ensures international patients receive a warm, stress-free welcome the moment they land. By combining world-class hospitality with trusted medical expertise, we are redefining the healthcare journey — making it as seamless and supportive as possible from arrival to recovery.' Dubai welcomed over 691,000 people for medical treatments in 2023, with spending on healthcare services exceeding AED 1.03 billion (US$ 280 million). The emirate is rapidly positioning itself as a leading global destination for medical tourism, combining advanced healthcare with world-class luxury and personalised care. According to PRIME Health, international patient flows to Dubai have grown across diverse medical specialisms, with dentistry, dermatology, cardiology, and fertility treatments leading demand. Medical tourists increasingly seek Dubai's orthopaedic treatments, particularly joint replacement surgeries, and the city's range of the latest cosmetic treatments also remain popular with visitors. As part of its growing network, PRIME Health also operates medical centres within terminals one and three at Dubai International airport (DXB), providing convenient access to high-quality care for travellers. marhaba, which means 'welcome' in Arabic, was launched in the UAE to help passengers arriving in or departing from Dubai International airport. The popularity of meet & greet services has grown exponentially in line with Dubai's growth as a major international travel hub, and marhaba has continually expanded its product offering with a growing list of services and extra options designed to make the passenger airport experience as comfortable as possible. The marhaba brand is part of dnata, one of the world's largest air services providers. A trusted partner of over 300 airline customers, dnata offers ground handling, cargo, travel catering & retail services in over 30 countries across six continents.
